How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cell and Gene Therapy CDMO Services Market
- By Service Type: Process Development, Analytical Development and Testing, Clinical and Commercial Manufacturing, Regulatory Support Services, Fill-Finish and Packaging
- By Therapy Type: Chimeric Antigen Receptor T-cell (CAR-T) Therapy, Gene Editing (CRISPR, TALEN), Viral Vector Manufacturing (AAV, Lentivirus), Stem Cell Therapy, Oncolytic Virus Therapy
- By Cell Source: Autologous Cell Therapy, Allogeneic Cell Therapy
- By Manufacturing Scale: Clinical-Scale Manufacturing, Commercial-Scale Manufacturing
- By Technology Platform: Viral Vector-Based Platforms, Non-Viral Vector Platforms, mRNA-Based Platforms
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Process Development leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Cell and Gene Therapy CDMO Services Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Therapy Type 5
Cell Source 2
Manufacturing Scale 2
Technology Platform 3
Companies profiled
Lonza Group AG
Catalent Inc.
Thermo Fisher Scientific Inc.
WuXi AppTec
Sartorius AG
Cytiva (part of Danaher Corporation)
Boehringer Ingelheim BioXcellence
Samsung Biologics
Fujifilm Diosynth Biotechnologies
AGC Biologics
Paragon Bioservices (now part of Catalent)
Brammer Bio (now part of Thermo Fisher Scientific)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Catalent Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →WuXi AppTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cytiva (part of Danaher Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Boehringer Ingelheim BioXcellence
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Samsung Biologics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Fujifilm Diosynth Biotechnologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AGC Biologics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Paragon Bioservices (now part of Catalent)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Brammer Bio (now part of Thermo Fisher Scientific)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →ViveBiotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Oxford Biomedica
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cellares Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,537M by 2033 · 9.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Process Development48.7
- Analytical Development and Testing10.5
- Clinical and Commercial Manufacturing11.6
- Regulatory Support Services14.0
- Fill-Finish and Packaging15.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,319M → $3,104M · 11.3%
Europe$919.6M → $1,888M · 9.4%
Asia Pacific$839.7M → $1,979M · 11.3%
Latin America$519.8M → $1,068M · 9.4%
Middle East and Africa$399.8M → $899.5M · 10.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.902026
9.922027
9.922028
9.942029
9.942030
9.952031
9.972032
9.982033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Lonza Group AG21.2
- Catalent Inc.20.0
- Thermo Fisher Scientific Inc.11.7
- WuXi AppTec4.7
- Sartorius AG10.1
- Cytiva (part of Danaher Corporation)4.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type36.0%
Therapy Type15.9%
Cell Source18.0%
Manufacturing Scale18.2%
Technology Platform12.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe21.1
- Asia Pacific22.1
- Latin America11.9
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Lonza Group AG | 81 | 82 | 81 | 82 | 92 | 95 | 86 |
| Catalent Inc. | 71 | 90 | 75 | 90 | 72 | 68 | 78 |
| Thermo Fisher Scientific Inc. | 76 | 72 | 74 | 66 | 64 | 78 | 72 |
| WuXi AppTec | 79 | 68 | 69 | 62 | 65 | 79 | 70 |
| Sartorius AG | 70 | 72 | 66 | 66 | 64 | 64 | 67 |
| Cytiva (part of Danaher Corporation) | 56 | 56 | 63 | 60 | 57 | 58 | 58 |
| Boehringer Ingelheim BioXcellence | 60 | 52 | 45 | 64 | 59 | 58 | 56 |
| Samsung Biologics | 56 | 51 | 49 | 37 | 38 | 37 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Lonza Group AG
- Catalent Inc.
- Thermo Fisher Scientific Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Lonza Group AG | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Catalent Inc. | ✓ | ◐ | − | ◐ | ✓ | ◐ |
| Thermo Fisher Scientific Inc. | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| WuXi AppTec | ✓ | − | ◐ | ◐ | ◐ | ✓ |
| Sartorius AG | ◐ | ◐ | ◐ | ◐ | − | − |
| Cytiva (part of Danaher Corporation) | − | − | ◐ | − | ◐ | ◐ |
| Boehringer Ingelheim BioXcellence | ◐ | ◐ | − | ◐ | − | ◐ |
| Samsung Biologics | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Lonza Group AG86
2Catalent Inc.78
3Thermo Fisher Scientific Inc.72
4WuXi AppTec70
5Sartorius AG67
6Cytiva (part of Danaher Corporation)58
7Boehringer Ingelheim BioXcellence56
8Samsung Biologics45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Lonza Group AGCatalent Inc.
Challenger3
Strong scale, closing on the leaders.
Thermo Fisher Scientific Inc.WuXi AppTecSartorius AG
Contender1
Focused players with pockets of strength.
Cytiva (part of Danaher Corporation)
Niche2
Specialists in a single segment or region.
Boehringer Ingelheim BioXcellenceSamsung Biologics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Cell and Gene Therapy CDMO Services Market — a $422M beachhead inside a $6.83B market.
Beachhead (SOM)$422Mobtainable near-term
Serviceable (SAM)$2.42Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Process Development
Best fit — highest urgency & budget in Service Type.
Economic buyer78 fit
Analytical Development and Testing
Strong fit — clear ROI and a fast path to value.
End user69 fit
Clinical and Commercial Manufacturing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapy Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Cell Source
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel26%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cell and Gene Therapy CDMO Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified25%
Evaluation13%
Closed-won6%
$13.1KCAC
$52KLTV
4.0:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cell and Gene Therapy CDMO Services Market is a durable-growth opportunity — $2.57B by 2033, compounding at 9.3%.
TAM · 2025$1.26Btoday
TAM · 2033$2.57Bforecast
CAGR9.3%2027–2033
Cumulative$16.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.57BTotal addressable market
SAM$980MServiceable available market
SOM$161MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.3% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.57BLarge & growingTAM by 2033 at 9.3% CAGR
$980MServiceable nowreachable with today’s model
$161MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.00BBear6.0% CAGR
$2.57BBase9.3% CAGR
$3.29BBull12.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapy Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cell and Gene Therapy CDMO Services Market — a $6.14B market by 2033. Plan: grow share from 9.4% to 16.8%.
Market size · 2033$6.14Btotal addressable
Market CAGR5.9%2027–2033
Target share16.8%from 9.4% today
Revenue ambition$1.03Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.4% | 16.8% | On track |
| Revenue | $582M | $1.03B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 36.7% | 43.7% | Ahead |
| Customer retention | 91.5% | 96.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapy Type capability
A defensible second engine — invest in Therapy Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapy Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $113M capacity & capability investment
- Greenlight bolt-on M&A in Therapy Type
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cell and Gene Therapy CDMO Services Market conversation — a $844M market you can size, segment and defend in minutes.
Market size · 2033$844Mtotal opportunity
Growth7.6%CAGR to 2033
Addressable buyers1,645+accounts in scope
Typical ROI5.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.3×return on cost, year one
< 3 mopayback period
$93K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Lonza Group AGCatalent Inc.Thermo Fisher Scientific Inc.WuXi AppTecSartorius AGCytiva (part of Danaher Corporation)Boehringer Ingelheim BioXcellenceSamsung Biologics+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cell and Gene Therapy CDMO Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cell and Gene Therapy CDMO Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cell and Gene Therapy Related Products Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportCell Anemia Testing & Screening Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCell Assay Reagents Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportCell Based Collagen and Gelatin Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportCell Carcinoma Treatment Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportCell Clone Selection System Market
Market size, share, segmentation and regional forecast.
$753M market · 2025 base year
View reportCell Coating Inspector Market
Market size, share, segmentation and regional forecast.
$868M market · 2025 base year
View reportCell Control Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCell Count Reagent Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportCell Counter Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCell Countes Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCell Counting Devices Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.